Irving, TXNCT07807345Now EnrollingIRB Ready

Head & Neck Squamous Cell Carcinoma Clinical Trial in Irving, TX

Access cutting-edge head & neck squamous cell carcinoma treatment through this phase 1 clinical trial at a research site in Irving. Study-provided care at no cost to qualified participants.

Sponsored by Sutro Biopharma, Inc.

Quick Self-Assessment

See if you qualify for this Irving location

Preparing your pre-screening questions…

Expert Care in Irving

Access head & neck squamous cell carcinoma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related head & neck squamous cell carcinoma treatment provided free

Apply for This Irving Location

Check if you qualify for this head & neck squamous cell carcinoma clinical trial in Irving, TX

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Irving

    Convenient for TX residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Irving site if eligible
  4. 4Begin participation

About This Head & Neck Squamous Cell Carcinoma Study in Irving

This study is a first-in-human (FIH) Phase 1 open-label, multicenter study including three parts: * Part 1A is a dose escalation of STRO-006 monotherapy in selected tumor types reported to commonly express ITGB6. Part 1A will determine the safety, tolerability, pharmacokinetics (PK), and preliminary anti-tumor activity of STRO-006. * Part 1B is a dose expansion in one or more indications, as determined by the Sponsor, to further evaluate a STRO-006 monotherapy dose, examine anti-tumor activity, and determine the recommended Phase 2 dose (RP2D) of STRO-006 monotherapy. * Part 1C is a combination dose escalation to determine safety, tolerability, PK, and preliminary anti-tumor activity of STRO-006 combined with pembrolizumab.

Sponsor: Sutro Biopharma, Inc.

Who Can Participate

Inclusion Criteria

Histologically or cytologically documented refractory solid tumors that are recurrent or metastatic including: HNSCC (excluding EBV-positive nasopharyngeal carcinoma), NSCLC, esophageal/gastric cancer, colorectal cancer, endometrial carcinoma, urothelial carcinoma, and breast cancer (HR-positive \[HER2-positive or HER2-negative\] and TNBC subtype)
Age ≥ 18 years
Life expectancy of at least 3 months
Willingness and ability to comply with the study protocol and long
Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1-term follow-up (LTFU) assessments
Has received standard systemic therapies with known clinical benefit, or is considered inappropriate for such therapies, in the opinion of the investigator. In the dose escalation Phases (Parts 1A and 1C), there is no limit on the number of prior therapies
Expansion Phase (Part 1B) only: Up to two prior therapies are allowed. For participants with AGA-driven adenocarcinoma NSCLC up to four prior therapies are allowed
Measurable disease per RECIST v1.1.
Adequate hematologic and organ function

Exclusion Criteria

Prior anticancer treatment with an ADC with a TOP1 inhibitor payload. (Prior therapy with an ITGB6-targeted ADC is otherwise allowed.)
Prior anticancer therapy (prior to first dose of study treatment): chemotherapy within ≤ 2 weeks, ICI ≤ 3 weeks, ADCs ≤ 3 weeks, palliative radiation therapy ≤ 2 weeks, and major surgery ≤ 4 weeks of C1D1. If not specified, ≥ 5 half-lives or 2 weeks, whichever is longer, since administration of prior therapy must have elapsed
Residual Common Terminology Criteria for Adverse Events (CTCAE) v5 ≥ Grade 2 toxicity from prior anticancer therapy, with the exception of Grade 2 alopecia or Grade 2 peripheral neuropathy, which is controlled, and endocrinopathies secondary to prior ICI controlled by hormonal treatment. For Part 1C only: discontinued prior immunotherapy due to treatment-related toxicity
Untreated or active brain metastases and/or leptomeningeal disease
Participants with active ILD or active, non-infectious pneumonitis or a history of active pneumonitis ≤ 6 months from the first dose of study treatment
Significant, concurrent renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, neurological, cerebral, or psychiatric disease that could impact participation in this clinical trial
Previous solid organ or bone marrow transplantation
Concurrent participation in another therapeutic treatment trial

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Irving?

Yes, this clinical trial (NCT07807345) has an active research site in Irving, TX that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Head & Neck Squamous Cell Carcinoma Treatment Options in Irving, TX

If you're searching for head & neck squamous cell carcinoma treatment options in Irving, TX, this clinical trial (NCT07807345) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Irving research site is actively enrolling participants for this phase 1 clinical trial. You'll receive care from experienced head & neck squamous cell carcinoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all head & neck squamous cell carcinoma clinical trials near you to find additional studies recruiting in your area.

More Alzheimers Disease Trials in Irving, TX

See all alzheimers disease clinical trials recruiting in Irving — not just this study.

Browse Alzheimers Disease Trials in Irving →

Browse More Trials by Condition

Alzheimers Disease TrialsAtopic Dermatitis TrialsAll Conditions →

Ready to Join in Irving?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Irving, TX